Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities
Biotechnology Progress · 2024
DOI: 10.1002/btpr.3492 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2024. Verfasst von Fiona C Kanis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Paper, and Biomedical Engineering, Miami University, Oxford, Ohio, USA. Hauptthemen laut MEDLINE: Tryptamines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: PsyBio Therapeutics.
Abstract (Originalsprache)
N ‐methylated tryptamines, such as the hallucinogenic natural products, psilocybin and N,N ‐dimethyltryptamine (DMT), are gaining interest from the medical community due to their potential as next generation treatments for mental health disorders. The clinical relevance of these compounds has driven scientists to develop biosynthetic production routes to a number of tryptamine drug candidates, and efforts are ongoing to expand and further develop these biosynthetic capabilities. To that end, we have further characterized the substrate preferences of two enzymes involved in tryptamine biosynthesis: TrpM, a tryptophan N ‐methyltransferase from Psilocybe serbica , and PsiD, the gateway decarboxylase of the psilocybin biosynthesis pathway. Here, we show that TrpM can N ‐methylate the non‐native amino acid substrate, 4‐hydroxytryptophan, a key intermediate in the Escherichia coli ‐based recombinant psilocybin biosynthesis pathway. However, the ability to incorporate TrpM into a functional psilocybin biosynthesis pathway was thwarted by PsiD's inability to use N,N ‐dimethyl‐4‐hydroxytryptophan as substrate, under the culturing conditions tested, despite demonstrating activity on N ‐methylated and 4‐hydroxylated tryptophan derivatives individually. Taken together, this work expands upon the known substrates for TrpM and PsiD, further increasing the diversity of tryptamine biosynthetic products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical, Paper, and Biomedical Engineering, Miami University, Oxford, Ohio, USA.
- Department of Chemistry, Williams College, Williamstown, Massachusetts, USA.
- Department of Microbiology, Miami University, Oxford, Ohio, USA.
- Department of Microbiology and Cell Science, Institute of Food and Agricultural Sciences, University of Florida, Gainesville, Florida, USA.
ORCID-Profile: J Andrew Jones
Förderung
- PsyBio Therapeutics
Zitieren
APA
Kanis, F. C., Broude, C. N., Hellwarth, E. B., Gibbons, W. J., Sen, A. K., Adams, A. M., Wang, X., & Jones, J. A. (2024). Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities. Biotechnology Progress. https://doi.org/10.1002/btpr.3492
Vancouver
Kanis FC, Broude CN, Hellwarth EB, Gibbons WJ, Sen AK, Adams AM, et al. Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities. Biotechnology Progress. 2024. doi:10.1002/btpr.3492
BibTeX
@article{Kanis2024,
author = {Kanis, Fiona C and Broude, Caroline N and Hellwarth, Elle B and Gibbons, William J and Sen, Abhishek K and Adams, Alexandra M and Wang, Xin and Jones, J Andrew},
title = {Evaluation of TrpM and PsiD substrate promiscuity reveals new biocatalytic capabilities},
journal = {Biotechnology Progress},
year = {2024},
doi = {10.1002/btpr.3492}
}
EUVIMED